The alkaloid galantamine was originally isolated from the green snowdrop Galanthus woronowii and is currently marketed as a drug for treatment of mild to moderate dementia in patients with Alzheimer's disease. In addition to a well-documented proficiency to inhibit acetylcholinesterase, galantamine has been reported to increase neuronal nicotinic ACh (nACh) receptor function by acting as a positive allosteric modulator. Yet there remains controversy regarding these findings in the literature. To resolve this conundrum, we evaluated galantamine actions at α4β2 and α7, which represent the nACh receptors most commonly associated with mammalian cognitive domains.
Introduction
Galantamine is an alkaloid originally isolated from the green snowdrop Galanthus woronowii. It is an inhibitor of the AChE enzyme and readily penetrates across the blood-brain barrier (Goh et al., 2011) . Currently, galantamine is marketed as a drug for treatment of mild to moderate dementia in patients diagnosed with Alzheimer's disease under the trade names Nivalin®, Razadyne® and Reminyl®. Further, reports have proposed potential therapeutic usefulness in schizophrenia, depression, bipolar disorder and as a treatment of drug abuse (reviewed by Ago et al. (2011) ). Compared to other AChE inhibitors marketed, for example, donepezil, galantamine is less potent at inhibiting the AChE enzyme, yet a report indicates that treatment benefits are comparable to, or even exceed those, of more potent inhibitors with respect to specific clinical outcome measures (Wilcock et al., 2003) . The efficient therapeutic effect has been speculated to originate from additional positive modulatory effects of galantamine at neuronal nicotinic ACh receptors (nACh receptors) (Samochocki et al., 2000; Samochocki et al., 2003; Wilcock et al., 2003) .
Galantamine was first suggested to have direct actions on nACh receptors in 1993 by Pereira et al. (1993b) . Using singlechannel recordings from rat hippocampal neurons, galantamine was observed to activate at low concentrations (0.1-10 μM) and cause receptor desensitization at a high concentration (10 μM). These actions were insensitive to the nACh receptor antagonists MLA (methyllycaconitine) and α-bungarotoxin but sensitive to applications of a monoclonal antibody called FK1 (anti-ubiquitin antibody) . From this, it was proposed that nACh receptors were activated via galantamine binding to a non-orthosteric (non ACh-binding) site. In the following years, several reports investigated the agonist effects of galantamine at different nACh receptor subtypes with varying results, albeit a common trait was an inability to evoke whole-cell currents (Pereira et al., 1994; Storch et al., 1995; Cooper et al., 1996) .
Potentiation of ACh-evoked currents or positive allosteric modulation (PAM) of methyl-galantamine was proposed by Storch et al. (1995) . Using whole-cell recordings of phaeochromocytoma cells (PC12), the addition of methylgalantamine (0.4 μM) was found to double the response compared with that obtained for ACh (100 μM) applications alone. Similar results were observed in rat hippocampal neurons (Schrattenholz et al., 1996) . Using anatoxin as an agonist, galantamine resulted in 59% potentiation of α7 nACh receptor currents in this study. PAM actions by galantamine were also evaluated at cloned α4β2, α6β4 and α3β4 nACh receptors and a chicken/mouse α7/5-HT 3 chimeric receptor stably expressed in HEK293 cells (Samochocki et al., 2000; Samochocki et al., 2003) . In these studies, positive modulation ranged from 50 to 100% depending on the receptor subtype.
In this context, it is noteworthy that the same group of principal investigators performed the majority of the early studies. A later observation of modest galantamine PAM activity ranging from 9 to 22% at the wild-type human α7 nACh receptor expressed in oocytes by Texidó et al. (2005) seemed to corroborate their findings; however, not all reports confirm PAM activity of galantamine. In a comparison with other AChE inhibitors, the activity of galantamine at nACh receptors in rat brain slices could be fully attributed to increased ACh levels resulting from AChE activity (Roman et al., 2005) . Further, Akk and Steinbach (2005) observed no PAM activity in singlechannel experiments using the mouse muscle nACh receptor, and Schildan et al. (2003) was unable to positively modulate nicotine-elicited responses at cloned α4β2 receptors in HEK293 cells.
In addition to the functional characterization, a number of biophysical studies were performed in an attempt to identify and characterize a binding site for galantamine. In early radioligand displacement studies, galantamine (up to 100 μM) did not inhibit binding of nicotine, epibatidine, methyllycaconitine or α-bungarotoxin to receptors from rat brain or SH-SY5Y cells (Dajas-Bailador et al., 2003) . This suggests that galantamine does not bind to the orthosteric ACh-binding site. However, Hamouda et al. (2013) later carried out studies with higher concentrations of galantamine and found displacement of tritiated ACh in muscle-type nACh receptors with an IC 50 value of 3 mM. Potential binding in the nACh receptor agonist-binding pocket at high concentrations seems in agreement with a co-crystal structure of galantamine and the ACh binding protein where electron density from galantamine was observed within the ACh binding-pocket (Hansen and Taylor, 2007) .
Methyl-galantamine was radiolabelled (Schildan et al., 2003) , presumably in an attempt to measure direct binding and identify the binding site, but no actual binding studies were reported suggesting that specific binding was not observed. Recent photo-affinity labelling revealed potential galantamine binding at three sites distinct from the AChbinding site on the Torpedo nACh receptor (Hamouda et al., 2013) . These were all located on the extracellular domain of the Torpedo receptor but intriguingly did not overlap with amino acids located on β-strand 10, which were suggested as binding site residues based on site-directed mutagenesis studies (Ludwig et al., 2010) .
From a therapeutic perspective, enhancing cholinergic neurotransmission by simultaneously inhibiting ACh hydrolysis and potentiating nACh receptor function might seem a highly attractive approach for the symptomatic treatment of Alzheimer's disease. Nevertheless, it follows from above that the evidence supporting this dual mode of action for galantamine is at best fragmented. Regarding the proposed PAM activity, the actual level of reported modulation appears variable (9-100%), and potentiation was not observed in all studies. With respect to (a) potential binding site(s), the actual physical location(s) in neuronal nACh receptors remains elusive. As a further complication, several studies eluding to galantamine modulation of nACh receptor function actually rely on data for methyl-galantamine or physostigmine (Cooper et al., 1996; Okonjo et al., 1991; Pereira et al., 1993a, b; Schildan et al., 2003; Schrattenholz et al., 1996) .
In the present study, we report a coherent set of data exploring the effects of galantamine at α7, (α4) 3 (β2) 2 , (α4) 2 (β2) 3 and (α4) 3 (β4) 2 nACh receptors expressed in Xenopus laevis oocytes. To investigate whether the choice of expression system might influence findings, we additionally performed patch-clamp recordings on α7 receptors stably expressed in HEK293 cells. Essentially, we did not observe significant positive allosteric modulation by galantamine at any of the receptor subtypes explored. Instead, galantamine at high concentrations (≥10 μM) behaved as a non-selective inhibitor with a mechanism of action consistent with openchannel pore blockade.
Methods

Molecular biology
Human α7, α4, β2 and β4 nACh receptor subunits were cloned and inserted into expression vectors as described previously (Timmermann et al., 2007) . Plasmid cDNAs were linearized using a downstream Not I restriction site and purified. cRNA was prepared and capped from the linearized cDNA using the mMessage mMachine T7 transcription kit according to the manufactures protocol. Purified cRNA was obtained using the RNeasy mini kit whereafter the cRNA was aliquoted and stored at a concentration of 0.5 μg·μL
À1
at À80°C until further use.
Expression of nACh receptors in Xenopus laevis oocytes
Mature female X. laevis frogs were anaesthetized with 0.17% tricaine in 0.06% sodium bicarbonate solution for 15 min, after which the loss of righting reflex was confirmed. Frogs were then transferred to an ice-cold base where surgeries were performed. Ovary lobes were removed by surgical incision and kept in ice-cold saline solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 5 mM HEPES hemisodium, pH 7.4). The Animal Ethics Committee of the University of Sydney approved the protocol for this (Protocol number: 2013/5915) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
To obtain isolated oocytes, ovary lobes were sliced into small pieces using surgical knives and defolliculated by collagenase treatment. Stages V and VI oocytes were injected with a total of~25 ng of cRNA mixtures encoding either α7 with RIC3 in a 5:1 ratio, α4 and β2 subunits in ratios of 4:1 and 1:4 or α4 and β4 in a 4:1 ratio. The 4:1 and 1:4 ratios were used to obtain enriched populations of 3α:2β or 2α:3β stoichiometry receptors respectively. Injected oocytes were incubated for 2-5 days at 18°C in a saline solution [96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES (hemisodium, pH 7.4)] supplemented with 2.5 mM sodium pyruvate, 0.5 mM theophylline and 50 μM kanamycin.
Oocyte electrophysiology
Electrophysiological recordings from X. laevis oocytes were performed using the two-electrode voltage-clamp technique as described previously (Mirza et al., 2008) . Briefly, oocytes were placed in a custom-built recording chamber and continuously perfused with a saline solution. Unless specifically mentioned, the saline solution was Ca 2+ free (115 mM NaCl, 2.5 mM KCl, 1.8 mM BaCl 2 , 10 mM HEPES and adjusted to pH 7.4 with NaOH). In specific α7 receptor experiments, Ca 2+ was included in the saline solution (115 mM NaCl, ACh and galantamine were dissolved in milliQ water as 10 mM stock solutions and stored at À20°C until further use. NS1738 was dissolved as a 10 mM stock solution in DMSO and stored at À20°C until further use. Fresh serial dilutions of compounds were prepared in saline solution on the day of the experiment. This was performed unblinded in the sense that the experimenter was aware of which compound was being diluted. Any leftover diluted solution was discarded at the end of the day.
To obtain precise control of the solution exchange in the immediate vicinity of the oocyte, a 1.5 mm inner diameter capillary tube was placed approximately 2 mm from the oocyte. By way of this capillary, oocytes were continuously perfused with saline solution or 'test application' (saline solution with ACh, galantamine, NS1738 or mixtures thereof) at a flow rate 2.0 mL·min À1 . Low-volume teflon tubing (inner diameter of 0.5 mm) connected the capillary to a Gilson 231XL autosampler (Gilson, Middleton, WI, USA), and all applications as well as triggering events were controlled using the Gilson 735 software suite. During washout periods, the 2.0 mL·min À1 solution flow rate was maintained using a Gilson Minipuls 3 pump whereas test applications were applied using a Gilson 402 syringe pump. This application methodology has two advantages: (i) it ensures rapid solution exchange (order of a few seconds) in the vicinity of the oocyte both when switching from saline solution to test application and when switching back; and (ii) it ensures identical and constant flow rate of 2.0 mL·min À1 during test applications. The washout time interval between triggered recording events was from 2 to 5 min depending on receptor type and ACh concentration applied. The washout periods were chosen such that they were long enough to ensure reproducible receptor deactivation between individual applications yet short enough to allow full concentration-response relationships for ACh, galantamine or NS1738 to be obtained at each oocyte (maximal time for a complete experiment less than 1 h).
Experimental protocol for oocyte experiments
A complete experiment on a single oocyte contains all initial control applications as well as the full planned concentration-response relationship for ACh, galantamine or NS1738. To ensure reproducibility of ACh-evoked current amplitudes, a set of initial control applications was performed. These were as follows: two to four ACh control applications (~EC 20 , 1-30 μM depending on receptor type); an ACh max application (maximum efficacious ACh concentration EC 100 , 1-10 mM depending on receptor type); and two to four additional ACh control applications. Following the initial control applications, the actual concentration-response relationships of ACh, galantamine or NS1738 were obtained. In all experiments a pre-incubation protocol was used. This entailed an initial reference ACh control application (pre-incubation with saline solution) followed by test applications with increasing concentrations of galantamine/NS1738. These test applications consisted of pre-incubation of galantamine/NS1738 after which the same concentrations of galantamine/NS1738 were co-applied with ACh control . A similar pre-incubation protocol was used for ACh concentration-response relationships both in the presence and absence of galantamine at α7 receptors. This entailed pre-incubation with saline solution or 30 μM galantamine followed by coapplication of saline or 30 μM galantamine with increasing concentrations of ACh. All applications and washout time intervals were executed and controlled by the Gilson 231XL autosampler according to a pre-programmed method in the Gilson 735 software suite. Once initiated, experiments were completed unattended and thus blinded in the sense that there was no user intervention during data acquisition. Final datasets were assembled from a minimum of n = 5 experiments conducted on a minimum of two batches of oocytes. A batch of oocytes originated from one X. laevis frog and was used for maximally 1 week. As fresh compound serial dilutions were prepared each day, it follows that final datasets were obtained from testing at oocytes from a minimum of two frogs and two independent compound preparations. No single datapoint was excluded from calculations in a dataset. However, all data from an individual oocyte were omitted in cases where (i) the initial control applications did not result in reproducible ACh-evoked responses; or (ii) the full planned concentration-response relationship was not successfully obtained (incomplete experiment).
Expression of the α7 nACh receptor in HEK293 cells
HEK293 cells were stably transfected with cDNA encoding human α7 nACh receptor as well as cDNA encoding RIC3. Briefly, cells were maintained at 37°C/5% CO 2 in DMEM containing 10% FCS, 2 mM penicillin/streptomycin/glutamine, 10 mM HEPES, 0.1 mM NEAA, 1 mM sodium pyruvate, and antibiotics G418 and puromycin. When being prepared for patching, cells were seeded at a density of 8 × 10 4 cells·mL À1 in T25 flasks using the same media without the antibiotics. Following incubation at 37°C for 2 days, cells were incubated for an additional 24 h at 33°C to enhance receptor expression. To detach cells for electrophysiology, the media were removed and cells were rinsed twice with PBS. Cells were then treated with Accutase for 5 min at 37°C to detach cells from the flask and placed on a rocking platform for 10 min. Next, cells were pelleted by centrifugation, re-suspended in recording buffer (see section: HEK293 cell patch-clamp electrophysiology) and kept in suspension on a rocking platform until patching.
HEK293 cell patch-clamp electrophysiology
HEK293 cell patch-clamp recordings were performed using the Dynaflow Resolve® system (Cellectricon, Mölndal, Sweden) and an EPC10 USB amplifier (HEKA Electronik, Germany). The recording buffer contained 137 mM NaCl, 5 mM KCl, 10 mM HEPES, 10 mM D-glucose, 2.5 mM CaCl 2 and 1 mM MgCl 2 , pH 7.4 with NaOH and osmolarity adjusted to 295-300 mOsm·L À1 . Fresh ACh, galantamine or NS1738 dilutions were prepared in recording buffer on each experimental day. This was performed unblinded in the sense that the experimenter was aware of which compound was being diluted. Electrodes were pulled from borosilicate glass using a Sutter Instruments P2000 electrode puller (Sutter Instrument Company, Novato, CA, USA) and had a resistance of 1.5-2.0 MΩ. Electrodes were backfilled with an intracellular solution containing 120 mM K gluconate, 5 mM KCl, 10 mM HEPES, 10 mM EGTA, 2 mM NaATP and 1 mM NaGTP, pH 7.2 with KOH and osmolarity adjusted to 285mOsm·L À1 . Following establishment of the whole-cell configuration, the membrane potential was clamped at À70 mV and cells with a series resistance of less than 10 MΩ were accepted for further experimentation. Here, α7 nACh receptors were subjected to a series of applications by moving the patched cell in front of the individual channels of the Dynaflow system. A typical episodic recording event contained the following pre-programmed elements. Initial application of recording buffer for 20 s followed by galantamine pre-application for 40 s (except for the 0.01 μM concentration which was pre-applied for 60 s). ACh at EC 20 (previously determined in the Dynaflow system to be 80 μM on the human α7 HEK293 cell line) was then co-applied with galantamine for 250 ms. The process was repeated for each concentration of galantamine, NS1738 as well as control ACh responses. A complete experiment contains all necessary control applications and a full concentration-response relationship for galantamine or NS1738 on the same cell. Final datasets were assembled from a minimum of n = 5 experiments obtained on a minimum of two experimental days.
Data analysis
Two-electrode voltage-clamp data were analysed using Clampex 10.2 (Molecular Devices). During analysis, all episodic traces from an experiment were first overlain and baseline subtracted simultaneously. This was performed using the built-in baseline-subtraction routine in Clampex, where the means between a cursor pair placed within the initial~15 s baseline period was subtracted from all recorded datapoints. Responses to applications were then quantified from all traces simultaneously as either (i) peak current amplitudes between a cursor pair covering the application time or (ii) area under the curve (net charge) for the full duration of the recorded trace. Hence, data were quantified in a blinded manner in the sense that baseline subtraction and identification of the response to applications were performed automatically by Clampex 10.2 following simple user setting of a cursor pair. Patch-clamp data were evaluated using PatchMaster (HEKA Electronik), and responses were quantified as peak current amplitudes. This was performed using manual setting of baseline and peak current amplitude cursors and hence unblinded. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All fitting and statistical calculations were performed using GraphPad Prism 7 (GraphPad Software). A monophasic Hill equation was used for all non-linear regression calculations. When evaluating for galantamine activity, the ratios between peak current amplitudes (or net charge values) and the respective ACh control applications were calculated as % (I Galantamine * 100%/I ACh_control ). Note that no activity equals 100% with this calculation method. For inhibition plots, data were fitted with the slope set to 1 and remaining activity at infinitely high galantamine concentrations set to 0. When evaluating for NS1738 activity, the differences between peak current amplitudes (or net charge values) and the respective ACh control applications were calculated as % [(I Galantamine À I ACh_control ) * 100%/I ACh_control ]. Note that no activity equals 0% with this calculation method. For modulation plots, data were fitted with the slope set to 1. For ACh concentration-response relationships, datasets for each oocyte were initially normalized to the maximal fitted peak current amplitude and thereafter averaged. The averaged data were then fitted with the slope set to 1 and efficacy at infinitely low ACh concentrations set to 0. Pairwise statistical analysis was performed using Student's t-test, and P < 0.05 was set as the significance level.
Materials
Galantamine hydrobromide analytical standard was purchased from PhytoLab GmbH & Co. KG (Vestenbergsgreuth, Germany). Restriction enzymes were from New England Bio Labs Inc. (Ipswich, Massachusetts, USA), and DNA and RNA purification kits were from QIAGEN N.V. (Venlo, The Netherlands). mMessage mMachine T7 transcription kits were from ThermoFisher Scientific (Massachusetts, USA). ACh, kanamycin, theophylline, tricaine, collagenase, HEPES, all salts and other chemicals not mentioned specifically were purchased from Sigma-Aldrich Co. LLC (St. Louis, Missouri, USA) and were of analytical grade. HEK293 cells were obtained from American Type Culture Collection (Manassas, Virginia, USA.). All cell culture materials, that is, DMEM, nonessential amino acid cell culture supplement (NEAA), FCS, sodium pyruvate, penicillin, streptomycin, glutamine, geneticin (G418), puromycin and accutase were from Invitrogen (Mulgrave, VIC, Australia).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
As outlined in the introduction, galantamine has been reported to increase nACh receptor function by acting as a PAM, albeit there is some controversy regarding this in the literature. In order to clarify this conundrum, we evaluated the actions of galantamine at the two most abundant nACh receptor subtypes in the mammalian brain, the homomeric α7 and the heteromeric α4β2 receptors. Recently, it was shown that heteromeric nACh receptors such as α4β2 exist in two distinct stoichiometries with a different ratio between the two subunit types, for example, (α4) 3 (β2) 2 and (α4) 2 (β2) 3 ; hence, we tested galantamine on both α4β2 stoichiometries (Zwart and Vijverberg, 1998; Nelson et al., 2003; Harpsøe et al., 2011; Mazzaferro et al., 2011) . Further, to assess for a potential influence of the β subunit, we additionally tested galantamine at the α4β4 nACh receptor in the (α4) 3 (β4) 2 stoichiometry. Xenopus laevis oocytes were injected with cRNA encoding the desired subunits and subjected to two-electrode voltage-clamp electrophysiology. Biased cRNA ratios (e.g. 4:1 or 1:4 of α4:β2) were used to enhance expression of specific stoichiometries of heteromeric nACh receptors as previously described (Timmermann et al., 2012) .
Testing for agonistic properties of galantamine at nACh receptors expressed in oocytes
Before commencing on studies of modulatory actions, we investigated whether galantamine displayed any direct agonistic effects at α7, (α4) 3 (β2) 2 , (α4) 2 (β2) 3 and (α4) 3 (β4) 2 nACh receptors. For this, galantamine was applied by itself in concentrations ranging from 10 nM to 100 μM. No galantamine-evoked responses were observed at any of the receptors types irrespective of the applied concentrations (representative traces in Figure 1 ; note the lack of receptor activation during the pre-incubation periods). On average, galantamine applications did not yield responses that differed >1% from the baseline in any case (n = 5 for α7, n = 6 for (α4) 3 (β2) 2 , n = 7 for (α4) 2 (β2) 3 and n = 6 for (α4) 3 (β4) 2 ). Hence, in agreement with previous data (Pereira et al., 1994; Storch et al., 1995; Cooper et al., 1996) , these data establish that galantamine does not have agonist properties at the most common nACh receptors to evoke any measurable whole-cell currents.
Testing for modulatory properties of galantamine at nACh receptors expressed in oocytes
We next explored whether galantamine exhibits positive modulatory actions at the four nACh receptors. For this, oocytes were pre-incubated with galantamine for~30 s prior to co-application of the same concentration of galantamine with a submaximal concentration of ACh (ACh control ) for 30 s. Five concentrations of galantamine ranging from 10 nM to 100 μM were evaluated. The ACh control concentrations were chosen for each receptor to reflect typically utilized activation levels in previous modulator studies (Timmermann et al., 2007; 2012) . The values were as follows: 30 μM for α7 and (α4) 3 (β2) 2 , 1 μM for (α4) 2 (β2) 3 and 10 μM (α4) 3 (β4) 2 . A pre-incubation protocol was used to enable
Figure 1
Effects of galantamine and NS1738 at nACh receptors expressed in Xenopus laevis oocytes. Xenopus oocytes were injected with cRNA mixtures containing nACh receptor subunits and subjected to two-electrode voltage-clamp electrophysiology as described in Methods. (A-E) Representative traces are seen for galantamine at α7 (A), (α4) 3 (β2) 2 (B), (α4) 2 (β2) 3 (C), (α4) 3 (β4) 2 (D) and for NS1738 at α7 (E). Following pipette insertion, the oocyte membrane potential was clamped at À60 mV and several rounds of ACh control (1-30 μM), ACh max (1-10 mM) were applied to ensure baseline stability and the ACh max reference point (note only the ACh max trace shown). Full concentration-response relationships for galantamine (10 nM to 100 μM) or NS1738 (0.316 to 31.6 μM) were next obtained using a pre-incubation protocol. This entailed~30 s application of galantamine/NS1738 alone [or saline solution (buffer) for the ACh control reference trace] followed by co-application of ACh control with the same concentration of galantamine/NS1738 for~30 s. The representative traces were baseline subtracted, and the bars above each trace represent the application periods and concentrations of galantamine/NS1738 and ACh. For clarity, the majority of the 'wash-out' periods (2-5 min) between each trace are omitted. equilibration of galantamine with its potential binding pocket before activation of the receptor. Such a protocol represents best practice for receptors with pronounced desensitizing intrinsic properties such as α7.
Representative current traces for experiments with α7 are depicted in Figure 1A . No significant increases in peak current amplitudes from the ACh control applications indicative of PAM activity were noted with galantamine co-applications in the 10 nM to 100 μM range. At higher concentrations, however, concentration-dependent inhibition of the ACh control -evoked peak current amplitudes were observed with 77 ± 1 and 33 ± 1% (n = 5) remaining at the 10 and 100 μM concentrations respectively. This inhibitory activity represented a significant change.
Overall, a similar scenario was observed for the (α4) 3 (β2) 2 , (α4) 2 (β2) 3 and (α4) 3 (β4) 2 nACh receptors as depicted by representative traces in Figure 1B -D. No single concentration of galantamine gave rise to increased current amplitudes indicative of PAM activity. Inhibition of the ACh controlevoked peak current amplitudes were noted at the higher concentrations in particular for 3α:2β stoichiometry receptors. At the 100 μM galantamine concentration, only 47 ± 9% (n = 6) and 14 ± 1% (n = 6) remained for (α4) 3 (β2) 2 and (α4) 3 (β4) 2 , respectively, whereas less inhibition was observed at (α4) 2 (β2) 3 receptors with 68 ± 8% (n = 7) remaining peak current amplitude.
The two-electrode voltage-clamp set-up utilized for these experiments is regularly employed to evaluate the actions of modulators with various efficacy levels at α4β2 nACh receptors and GABA A receptors (Olsen et al., 2014; Ahring et al., 2016) . To verify that activity of modulators is also detectable at α7 receptors, we tested NS1738. As demonstrated by Timmermann et al. (2007) , this compound is characterized by exhibiting relatively subtle positive modulation of α7 receptors with marginal effect at desensitization properties. Hence, NS1738 represents a good candidate for validating the capability to detect even low-level positive modulation at α7 receptors. With NS1738, we observed robust concentration-dependent PAM activity as evidenced by representative traces in Figure 1E . The responses were well approximated by the Hill equation with a derived EC 50 value of 4.8 μM and maximal response of 440% for n = 8 experiments (Figure 2A ). These data are in good agreement with previous data from oocytes (EC 50 = 3.4 μM and E max = 322%) by Timmermann et al. (2007) proving that potential PAM activity of a given compound is readily detectable in our set-up.
The increase in inhibitory activity of galantamine at increasing concentrations suggests specific interactions of the compound with nACh receptors. To investigate this, the percentage remaining peak current amplitudes were plotted as a function of the galantamine concentrations,
Figure 2
NS1738 modulation and galantamine inhibition of ACh-evoked nACh receptor currents from Xenopus oocytes. Peak current amplitudes from experiments illustrated by representative traces in Figure 1 were normalized to the amplitude of the respective prior reference ACh control applications in the absence of galantamine/NS1738 as described in Methods. (A, B) Normalized current amplitudes were plotted as means ± SEM as a function of the galantamine/NS1738 concentrations for the receptors indicated and fitted to the Hill equation by non-linear regression. Results from the fitting routines with galantamine were: α7, pIC 50 = 4.3 ± 0.03, n = 5; (α4) 3 (β2) 2 , pIC 50 = 4.1 ± 0.2, n = 6; (α4) 2 (β2) 3 -the inhibitory level at the maximal concentration of galantamine is too low to allow for robust fitting -n = 7; (α4) 3 (β4) 2 , pIC 50 = 4.9 ± 0.03, n = 6. Results for NS1738 are indicated in the panel.
Figure 3
Effects of galantamine at the α7 nACh receptor expressed in Xenopus oocytes using alternative experimental conditions. The α7 nACh receptor was expressed in Xenopus oocytes and subjected to two-electrode voltage-clamp experimentation as described in brief in the Figure 1 legend. (A) Representative traces of ACh-evoked currents in the presence or absence of galantamine (1 nM to 100 μM). In these experiments, the buffer contained Ca 2+ , and oocyte membrane potentials were clamped at À70 mV. The ACh control concentration of 250 μM represented approximate EC 50 (average of n = 9). (B) Representative traces of ACh-evoked currents in the presence or absence of galantamine (1 pM to 10 μM). In these experiments, the buffer contained Ca 2+ , and the membrane potential was clamped at À70 mV. The ACh control concentration of 30 μM represented approximate EC 10 (n = 15). (C, D) The peak current amplitudes from experiments illustrated by representative traces in (A) and (B), respectively, were normalized to the respective prior reference ACh control applications in the absence of galantamine as described in Methods. Normalized current amplitudes were plotted as means ± SEM or means ± SD as a function of the galantamine concentrations and fitted to the Hill equation by non-linear regression. Results from the fitting routines are indicated in the panels. SD values were used in (D) as SEM values were smaller than the symbol size. (E) Representative traces of ACh-evoked currents in the presence or absence of galantamine (100 nM to 1 μM). In these experiments, the buffer was Ca 2+ -free, and the membrane potential was clamped at À60 mV. The ACh control concentration of 10 μM represented approximate EC 5 (average of n = 9). and datapoints were fitted by non-linear regression ( Figure 2B ). For α7, (α4) 3 (β2) 2 and (α4) 3 (β4) 2 receptors, data were well approximated by sigmoidal inhibition curves. Derived IC 50 values of 55 and 78 μM were observed for α7 and (α4) 3 (β2) 2 receptors, respectively, whereas a higher potency of 12 μM was observed at (α4) 3 (β4) 2 receptors. For the (α4) 2 (β2) 3 receptor, inhibition was only observed at the highest tested concentration, which is insufficient to allow for robust fitting.
Testing for modulatory properties of galantamine using alternative experimental conditions
To our knowledge, only one previous study describes positive modulatory properties of galantamine at α7 nACh receptors expressed in Xenopus laevis oocytes. Texidó et al. (2005) reported 9.6% potentiation by 100 nM galantamine co-applied with 500 μM ACh whereas larger potentiation of 22% was observed in combination with 250 μM ACh. Arguably, efficacy levels of that magnitude reside at the limit of detection irrespective of the set-up utilized. Nevertheless, as the effects in this study were observed utilizing concentrations of ACh that were 10-fold higher than our standard protocol and included Ca 2+ in the buffer, we retested galantamine at α7 receptors mimicking the condition used by Texidó et al. (2005) .
Representative traces from experiments with galantamine in concentrations ranging from 1 nM to 100 μM coapplied with an ACh control concentration of 250 μM are seen in Figure 3A . From the traces, it is evident that peak current amplitudes at lower galantamine concentrations (<10 μM) are similar to that of the ACh control trace whereas inhibition is observed at the highest concentration. At 100 nM galantamine, the most efficacious concentration reported by Texidó et al. (2005) , the mean peak current amplitude was 100 ± 4% (n = 8) that of ACh control alone, which does not represent a significant difference. The collective dataset was plotted and fitted by non-linear regression as described above ( Figure 3C ). The derived IC 50 value of 65 μM was not significantly different from the 55 μM observed with our standard protocol using an ACh control concentration of 30 μM.
To discount the possibility that the concentrations of galantamine used were too high, we tested lower concentrations ranging from 1 pM to 10 μM in Ca 2+ containing buffer. No positive modulatory actions were noted ( Figure 3B, D) . At 1, 10, 100 pM and 1 nM galantamine, the peak current amplitudes were 98 ± 0.4, 97 ± 0.8, 97 ± 0.9 and 98 ± 1.4% (n = 15) that of the ACh control applications respectively. Finally, as PAM activity at Cys-loop receptors normally manifests itself with higher percentage modulation at low receptor activation levels (Ahring et al., 2016) , we tested 100 nM to 1 μM concentrations of galantamine with an ACh control concentration of 10 μM corresponding to approximately EC 5 . ACh control -evoked currents exhibited limited to no observable current decay as seen in Figure 3E . Nevertheless, even under these theoretically optimal conditions for observing PAM activity at α7 receptors, galantamine did not significantly increase peak current amplitudes from that observed with ACh control alone in n = 9 independent experiments (95 ± 2% at 100 nM, 92 ± 2% at 500 nM and 93 ± 3% at 1 μM galantamine).
Evaluating oocyte experiments using net charge calculations
Observed effects of a PAM could be the result of alterations in nACh receptor gating properties, desensitization properties or both simultaneously. When estimating PAM activity of a given compound from electrophysiological experiments, it is common to use peak current amplitude measurements as above. Yet, as peak current amplitudes are often perceived to represent channel activation properties, this might pose the question whether a modulatory effect at the desensitization properties could be masked by only using peak current measurements. In an oocyte system, the activation kinetics of macroscopic whole-cell currents are largely determined by the application system, and for fast desensitizing receptors such as α7, the measured responses represent a mixture of activating and desensitizing receptors for the duration of the agonist application. Hence, if a compound alters desensitization properties substantially, it would inherently alter measured peak current amplitudes. Nevertheless, some estimation of potential effects on desensitization properties is still a valuable addition to the description of a compound. One method of evaluating modulator-induced alterations in desensitization properties of nAChRs is to perform net charge calculations (Papke and Porter Papke, 2002) . Instead of relying on a single measurement (peak current amplitude), the total charge transported across the cell membrane during a set timeframe is integrated (area under curve). Such calculations are very sensitive to alterations in desensitization properties of fast desensitizing receptors such as α7.
When evaluated using net charge calculations, NS1738 positively modulates α7 receptors with a fitted EC 50 value of 4.2 μM and an E max value of 550% ( Figure 4A ). These values are overall similar to the respective values of 4.8 μM and 440% obtained using peak current analysis. While the fitted maximal response was larger when data were evaluated using net charge analysis, this difference was not significant. The subtlety of the differences corroborates observations by Timmermann et al. (2007) that NS1738 has relatively minimal effects at the desensitization properties of α7 receptors.
Net charge analysis of galantamine experiments using our standard protocol at α7, (α4) 3 (β2) 2 , (α4) 2 (β2) 3 and (α4) 3 (β4) 2 nACh receptors is depicted in Figure 4B . No single concentration of galantamine gave rise to significantly increased net charge values indicative of PAM activity at any of the receptor types. Inhibition of the ACh control -evoked values were noted at higher galantamine concentrations with derived inhibitory IC 50 values that were not significantly different from those observed using peak current analysis.
Analysis of the galantamine experiments performed at α7 receptors under conditions mimicking those of Texidó et al. (2005) (high ACh control concentration and Ca 2+ inclusion in the saline solution) is depicted in Figure 4C . As evident from the graphical overlay, derived data were virtually identical irrespective of whether they were the result of net charge integration or peak current analysis. Likewise, no noticeable differences were observed for experiments with lower concentrations of galantamine ( Figure 4D ). Finally, net charge evaluation of experiments at α7 receptors performed under theoretically optimal conditions for observing PAM activity (low ACh control concentration of 10 μM) revealed no significant effect of 100 nM, 500 nM or 1 μM galantamine in n = 9 independent experiments (91 ± 4, 91 ± 5 and 97 ± 3% respectively).
Figure 4
Examination of effects of galantamine and NS1738 in Xenopus oocyte experiments using net charge analysis. (A-D) Data illustrated in Figures 2A,  B and 3C, D, respectively, were re-analysed using net charge analysis (curve integration). Area under the curve from all experiments were normalized to the respective reference ACh control applications in the absence of galantamine/NS1738 as described in Methods. Normalized values were plotted as means ± SEM or means ± SD as a function of the galantamine/NS1738 concentrations for the receptors indicated and fitted to the Hill equation by non-linear regression. Results from the fitting routines are indicated in the panels except for (B) where the values for galantamine were: α7, pIC 50 = 4.1 ± 0.1, n = 5; (α4) 3 (β2) 2 , pIC 50 = 3.8 ± 0.2, n = 6; (α4) 2 (β2) 3 -the inhibitory level at the maximal concentration of galantamine is too low to allow for robust fitting -n = 6; (α4) 3 (β4) 2 , pIC 50 = 4.8 ± 0.04, n = 6. SD values were used in (D) as SEM values were smaller than the symbol size. Note that for (A), (C) and (D), the plots obtained from peak current amplitude measurements are shown in grey.
Testing for modulatory properties of galantamine at α7 nACh receptors expressed in HEK293 cells Samochocki et al. (2003) observed 100% PAM activity with a 0.5 μM concentration of galantamine at an α7/5-HT 3A chicken/mouse chimeric receptor activated by 3 μM ACh (~EC 50 for that receptor). For these experiments, the α7/5-HT 3A chimera was expressed in HEK293 cells and evaluated using patch-clamp electrophysiology. To rule-out that the observed lack of modulation at wild-type α7 nACh receptors was a consequence of utilizing Xenopus oocytes, we additionally performed patch-clamp recordings with HEK293 cells stably expressing wild-type α7 and RIC3 using the sensitive Dynaflow Resolve® system. This system is regularly used
Figure 5
Galantamine testing at the α7 nACh receptor expressed in HEK293 cells. Patch-clamp electrophysiology recordings were performed on α7 nACh receptor stably expressed in HEK293 as described in Methods. (A, B) Representative traces of ACh-evoked currents in the presence or absence of galantamine (A) or NS1738 (B) using the Dynaflow Resolve® system. Galantamine or NS1738 was initially applied for 40 s (60 s for the 0.01 μM concentration) and thereafter co-applied with 80 μM ACh (~EC 20 ) for 250 ms. The membrane potential was clamped at À70 mV. (C, D) Baselinesubtracted peak current amplitudes were normalized to the prior ACh control application in the absence of galantamine/NS1738 as described in Methods. Normalized current amplitudes were plotted as a function of the galantamine/NS1738 concentrations and fitted to the Hill equation by non-linear regression. Results from the fitting routine are indicated in the panels.
to probe for effects of modulators at α7 receptors (Dunlop et al., 2009) . In full agreement with the oocyte recordings, no positive modulation was observed with galantamine concentrations ranging from 10 nM to 10 μM and marked inhibition was noted at higher concentrations of 100 μM ( Figure 5A ). In contrast, NS1738 modulation was readily detectable as evidenced by robust concentration-dependent PAM effects ( Figure 5B ). Plotting the peak current amplitudes as a function of the galantamine concentrations revealed a fitted curvature with an IC 50 value of 64 μM for n = 7 experiments similar to that observed with the oocytes ( Figure 5C ). The fitted concentration-response relationship of NS1738 revealed an EC 50 value of 2.6 μM and maximal response of 1600% for n = 7 experiments ( Figure 5D ). These values for NS1738 are in good agreement with previous patch-clamp observations (EC 50 = 1.6 μM and E max = 1170%) by Timmermann et al. (2007) .
Evaluating inhibitory properties of galantamine
From the above data, it appears that galantamine is not a PAM of common nACh receptors but instead inhibits ACh-evoked currents at high concentrations. Such inhibition could, for example, be due to competitive antagonism at the ACh binding sites or blockade of the channel pore. Given that overall similar levels of inhibition are observed irrespective of whether 10, 30 or 250 μM ACh was used for activating α7 receptors, it appears unlikely that galantamine is a competitive antagonist. To verify this, we performed full concentration-response relationships of ACh in the presence or absence of 30 μM galantamine. As seen in Figure 6A , normalized concentration-response relationships for ACh alone and ACh in the presence of 30 μM galantamine are largely overlapping with fitted EC 50 values of 280 and 340 μM respectively. This is inconsistent with a competitive antagonism profile.
While galantamine is not a permanently charged molecule, it is calculated that pKa value of 8.33 (Schrodinger, LLC; Shelley et al., 2007) suggests that a large proportion (~90%) of the molecules are positively charged in aqueous solutions at pH 7.4. We therefore explored whether galantamine might be a pore blocker at α7, (α4) 3 (β2) 2 , (α4) 2 (β2) 3 and (α4) 3 (β4) 2 nACh receptors. To observe potential pore blocking properties, we tested the extent to which a 30 μM concentration of galantamine inhibited ACh control -evoked peak current amplitudes at different holding potentials. The ACh control concentrations were chosen to reflect the EC 50 value at each of the four receptors. With all four receptors, a voltage-dependent block showing increased inhibition at more negative holding potentials was observed ( Figure 6B ).
Figure 6
Mechanism of the inhibitory action of galantamine at nACh receptors expressed in Xenopus oocytes. nACh receptors were expressed in Xenopus oocytes and subjected to two-electrode voltage-clamp experimentation as described in brief in the Figure 1 legend. (A) ACh concentration-response relationships were obtained at the α7 nACh receptor in the presence and absence of 30 μM galantamine (Gal). The peak current amplitudes evoked were fitted to the Hill equation and normalized as described in Methods. The fitted data derived are indicated in the panel, n = 10-11. (B) ACh-evoked currents from oocytes expressing the indicated receptors were obtained in the presence or absence of 30 μM galantamine (Gal) at membrane holding potentials ranging from À20 to À100 mV. Peak current amplitudes were normalized to that of the respective prior ACh control applications and plotted as a function of the holding potential. Normalized data were well approximated by linear regression. The fitted slopes were À0.75, À0.32, À0.38 and À0.46 for α7 (n = 8), (α4) 3 (β2) 2 (n = 6), (α4) 2 (β2) 3 (n = 6) and (α4) 3 (β4) 2 (n = 6) respectively.
For each respective receptor type, the data were well approximated by linear regression. A steeper slope was observed with α7 receptors whereas the other three receptor types displayed similar slopes. Hence, while the overall level of inhibition varied between receptor types, galantamine displayed inhibition consistent with pore blockage at the four receptors.
Discussion
The overall finding from our studies was that galantamine in a concentration range spanning two orders of magnitude (10 nM to 1 μM) did not exhibit PAM activity at α7 or heteromeric α4β2 receptors. With α7 receptors expressed in Xenopus oocytes, a range of different experimental conditions were attempted including variant ACh control concentrations (corresponding to receptor activation levels ranging from EC 5 to EC 50 ), assay buffers with or without Ca 2+ ions and very low concentrations of galantamine (down to 1 pM). Additionally, it was tested whether the choice of expression system could influence the results by performing experiments with α7 expressed stably in HEK293 cells. With α4β2 receptors, potential galantamine effects at both the 3α:2β and 2α:3β stoichiometries were tested, and to unravel a possible role of the β subunit, α4β4 receptors in the 3α:2β stoichiometry were tested as well. Our data are obviously in disagreement with parts of the galantamine literature, although as summarized in the introduction, that picture in itself is quite complex. There could be several reasons for this. First, most of the original data that led to claims of galantamine efficacy on nACh receptors comprised electrophysiological recordings from isolated neurons or cell lines such as PC12 that endogenously express nACh receptors (Pereira et al., 1993a, b; Storch et al., 1995; Schrattenholz et al., 1996) . While the utilized electrophysiological technique itself might represent state of the art, it is rarely possible to know exactly which receptors are responsible for the measured currents in cells of those origins. Instead, observed responses are often the result of activation of a plethora of receptors or even other signalling pathways. Second, the early data using cloned receptors (Pereira et al., 1994; Samochocki et al., 2000; Samochocki et al., 2003) were performed before the discovery that heteromeric nACh receptors assemble in different stoichiometries and before the discovery that RIC3 enhances the surface expression of the α7 receptor (Halevi et al., 2002; Lansdell et al., 2005; Harpsøe et al., 2011; Mazzaferro et al., 2011; Timmermann et al., 2012) . For heteromeric receptors, a lack of attention to stoichiometry invariably leads to high inter-cell variability as different cells express different receptor pools. With the α7 receptor, expression in, for example, HEK293 cells was obtained by using chimeric subunits, for example, a chicken/mouse α7/5HT 3 receptor Ludwig et al., 2010) . However, while the α7/5HT 3 receptor might resemble a wild-type α7 receptor in some regards, its characteristics are substantially different as evidenced by ACh being 50-100-fold more potent. Hence, a substantial part of the original data was not obtained in a manner that reflects the current best practice for characterizing nACh receptor modulators. Coupled with the fact that the measured levels of galantamine modulation were relatively minor in comparison with other known nACh receptor modulators, it is quite conceivable that the original observations were misrepresentative.
One exception from the above is the study by Texidó et al. (2005) where wild-type α7 receptors were expressed in Xenopus oocytes. Nevertheless, while this study concluded that galantamine acts as a PAM at α7 receptors, the observed effects were marginal. A galantamine concentration-response evaluation revealed significant modulation of 9.6 ± 2.7% but only at one specific concentration (0.1 μM). Besides being borderline significant, it is noteworthy that an efficacy of 10% is approximately 40-fold less than what is typically observed with the PAM NS1738 in similar experiments. This is despite the fact that NS1738 is considered a 'modestefficacy' PAM as it does not substantially alter the desensitization profile of α7 receptors.
Another observation from our experiments was that galantamine at higher concentrations (>1 μM) exhibited blockage of ACh control -evoked currents. This observation is in good agreement with previous findings where galantamine inhibited the α4β2 nACh receptor at concentration of 1 μM and higher (Samochocki et al., 2000; Samochocki et al., 2003) . While the inhibitory potency of galantamine in our experiments was similar at α7 and (α4) 3 (β2) 2 receptors, a higher corresponding potency at (α4) 3 (β4) 2 and lower potency at (α4) 2 (β2) 3 receptors suggest some β selectivity with heteromeric receptors.
Given that the inhibitory actions of galantamine could suggest a specific binding site, we evaluated the blockade mechanism further. Since galantamine is an inhibitor of the AChE enzyme, it might seem plausible that it is capable of binding in the ACh binding pocket of nACh receptors. However, concentration-response relationships of ACh at α7 in the absence or presence of galantamine had virtually identical EC 50 values indicating that galantamine does not interfere with normal ACh binding. We therefore tested whether the level of inhibition displayed voltage dependency. Indeed, galantamine exhibited increased inhibition at all four investigated nACh receptors as a function of the negative holding potential. For α7, the inhibition level increased approximately eightfold (from 8 to 67%) as the holding potential was changed fivefold (from À20 to À100 mV). Such voltage-dependent inhibition indicates blockade by an open-channel pore-blocking mechanism. It is well established that compounds with a size comparable to galantamine can act as open-channel pore blockers. Picrotoxin, for example, is a compound of comparable size that potently blocks GABA and glycine receptor channels (Kalueff, 2007) , but it is also shown to block the rat α7 nACh receptor with an IC 50 value of 195 μM (Erkkila et al., 2004) .
Concluding remarks
There have been numerous claims as to therapeutically relevant effects of galantamine at nACh receptors. These span reports of PAM activity and direct agonism that have been cited extensively in the review literature (e.g. see Echeverria et al., 2016) . However, we have not been able to reproduce these findings despite utilizing a variety of experimental conditions. This suggests that the pharmacological effects of galantamine in patients are solely the result of AChE inhibition, albeit other non-nACh receptor mechanisms cannot be excluded. Furthermore, the observed inhibitory actions of galantamine at nACh receptors are not likely to be relevant in a clinical context, as it is doubtful that patients would have the free brain concentrations necessary to obtain significant inhibition at nACh receptors.
